DOCSLIB.ORG

Predictive Value of Parkinsonian Primates in Pharmacological Studies, a Comparison Between the Macaque, Marmoset and Squirrel Monkey I

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Predictive Value of Parkinsonian Primates in Pharmacological Studies, a Comparison Between the Macaque, Marmoset and Squirrel Monkey I Downloaded from jpet.aspetjournals.org at ASPET Journals on October 1, 2021 NV PH JPET #247171 i HA,PH 1 Adjia Hamadjida, Philippe Huot Adjia Philippe Hamadjida, , JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on March 9, 2018 as DOI: 10.1124/jpet.117.247171 JPET Fast Forward. Published on Ma This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version.
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • A Systematic Review of Combination and High-Dose Atypical
    APPENDIX 12: STUDY CHARACTERISTICS OF INCLUDED STUDIES Number of Interventions/ Adjunctive Treatment APDs Failed Sample Author, Year Country Sponsor Comparators Medications Duration Prior to Size (Mean Dose) Allowed (Weeks) Study Grant from Stanley Medical research Institute, RIS+CLZ Benzodiazepines Janssen 515.6±138.7 mg/d CLZ for anxiety and/or AKDEDE et al. Pharmaceutica, and 42 Turkey biperiden for 6 weeks ≥3 30 (2005) THE Ritter 5.1±1.3 mg/day RIS EPS allowed if Foundation, the PLC+CLZ necessary William K. 414.3±96.9 mg/d CLZ Warren Medical Research Foundation ANIL YAGCIOGLU et 45 See Akdede 2006 al. (2005) AMI400+CLZ 400mg/d AMI and 300 Occasional mg/d CLZ intake of 49 Sanofi- AMI600+CLZ benzodiazepines, ASSION et al. (2008) Germany 6 weeks ≥1 16 Synthelabo 600 mg/d AMI and sedatives, or 300mg/d CLZ antidepressants PLC+CLZ allowed 300 mg/d CLZ 60 France and Novartis Phama RIS (H): median 9 mg/d AZORIN et al. (2001) Not reported 12 weeks ≥1 273 Canada S.A. CLZ: median: 600 mg/d Lorazepam or Janssen oxazepam for BONDOLFI et al. France and RIS (H): 6.4 mg/d 66 Research sleep induction 8 weeks ≥2 86 (1998) Switzerland CLZ: 291.2 mg/d Foundation or daytime sedation; 156 Systematic Review of Combination and High-Dose AAPs for Schizophrenia Number of Interventions/ Adjunctive Treatment APDs Failed Sample Author, Year Country Sponsor Comparators Medications Duration Prior to Size (Mean Dose) Allowed (Weeks) Study biperiden and procyclidine for EPS Supported by grants from Brain Research center, funded by the ARI+CLZ Antidepressants, Ministry of 15.5±7.1 mg/d ARI and 38 anticholinergics CHANG et al.
    [Show full text]
  • Journal of Pharmaceutical and Pharmacological Sciences Jaithliya T
    Journal of Pharmaceutical and Pharmacological Sciences Jaithliya T. J Pharma Pharma Sci 02: JPPS 122. Case Report DOI:10.29011/2574-7711.100022 Ashwagandha-The Nature’s Gift to Mankind Tanvay Jaithliya* Department of Pharmacy, Mewar University, Gangrar (Chittorgarh), India *Corresponding author: Jaithliya T, Department of Pharmacy, Mewar University, Gangrar (Chittorgarh) India. Tel: +91 01471291148; E-mail: [email protected] Citation: Jaithliya T (2017) Ashwagandha-The Nature’s Gift to Mankind. J Pharma Pharma Sci 02: 122. DOI: 10.29011/2574-7711.100022 Received Date: 15 March, 2017; Accepted Date: 10 April, 2017; Published Date: 17 April, 2017 Withania somnifera commonly known as Ashwagandha, In- Sindh, Gujarat and Rajasthan. It is also found in Nepal, China and dian Ginseng, poison gooseberry or winter cherry is a plant in the Yemen. solanaceae family or night shade family. It is used as one of the most powerful herbs in Ayurvedic healing, has been used since ancient times for a wide variety of conditions, and is most well- known for its restorative benefits. Traditionally, it is believed that a person who consumes this herbal medicine will gain horse like strength and vitality. Pathology Ashwagandha is prone to several pests and diseases. Leaf spot disease caused by alternariaalternata Is the most prevalent disease, which is most severe in the plains of Punjab, Haryana, Jammu and Kashmir and Himachal Pradesh? Bio deterioration of its pharmaceutically active components during leaf spot disease Description has been reported. This species is short, tender perennial shrub growing 14-30 Culinary Use inches tall. Leaves are dull green, elliptic, usually up to 10-12 cm long.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest Et A1
    US007964607B2 (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest et a1. (45) Date of Patent: Jun. 21, 2011 (54) PYRAZOLO[3,4-D]PYRIMIDINE FOREIGN PATENT DOCUMENTS COMPOUNDS EP 1460077 9/2004 WO 02085904 10/2002 (75) Inventors: Patrick Robert Verhoest, Old Lyme, CT WO 2004037176 5/2004 (US); Caroline ProulX-Lafrance, Ledyard, CT (US) OTHER PUBLICATIONS Wunder et a1, M01. PharmacoL, v01. 28, N0. 6, (2005), pp. 1776 (73) Assignee: P?zer Inc., New York, NY (U S) 1781. van der Staay et a1, Neuropharmacology, v01. 55 (2008), pp. 908 ( * ) Notice: Subject to any disclaimer, the term of this 918. patent is extended or adjusted under 35 USC 154(b) by 562 days. Primary Examiner * Susanna Moore (74) Attorney, Agent, or Firm * Jennifer A. Kispert; (21) Appl.No.: 12/118,062 Michael Herman (22) Filed: May 9, 2008 (57) ABSTRACT (65) Prior Publication Data The invention provides PDE9-inhibiting compounds of For US 2009/0030003 A1 Jan. 29, 2009 mula (I), Related US. Application Data (60) Provisional application No. 60/917,333, ?led on May 11, 2007. (51) Int. Cl. C07D 48 7/04 (2006.01) A61K 31/519 (2006.01) A61P 25/28 (2006.01) (52) US. Cl. ................................... .. 514/262.1; 544/262 (58) Field of Classi?cation Search ................ .. 544/262; 5 1 4/2 62 .1 See application ?le for complete search history. and pharmaceutically acceptable salts thereof, Wherein R, R1, (56) References Cited R2 and R3 are as de?ned herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in U.S.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • United States Patent (10 ) Patent No.: US 10,660,887 B2 Javitt (45 ) Date of Patent: *May 26 , 2020
    US010660887B2 United States Patent (10 ) Patent No.: US 10,660,887 B2 Javitt (45 ) Date of Patent : *May 26 , 2020 (54 ) COMPOSITION AND METHOD FOR (56 ) References Cited TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS U.S. PATENT DOCUMENTS 6,228,875 B1 5/2001 Tsai et al. ( 71 ) Applicant : Glytech , LLC , Ft. Lee , NJ (US ) 2004/0157926 A1 * 8/2004 Heresco - Levy A61K 31/198 514/561 (72 ) Inventor: Daniel C. Javitt , Ft. Lee , NJ (US ) 2005/0261340 Al 11/2005 Weiner 2006/0204486 Al 9/2006 Pyke et al . 2008/0194631 Al 8/2008 Trovero et al. ( 73 ) Assignee : GLYTECH , LLC , Ft. Lee , NJ (US ) 2008/0194698 A1 8/2008 Hermanussen et al . 2010/0069399 A1 * 3/2010 Gant CO7D 401/12 ( * ) Notice : Subject to any disclaimer, the term of this 514 / 253.07 patent is extended or adjusted under 35 2010/0216805 Al 8/2010 Barlow 2011/0207776 Al 8/2011 Buntinx U.S.C. 154 ( b ) by 95 days . 2011/0237602 A1 9/2011 Meltzer This patent is subject to a terminal dis 2011/0306586 Al 12/2011 Khan claimer . 2012/0041026 A1 2/2012 Waizumi ( 21 ) Appl. No.: 15 /650,912 FOREIGN PATENT DOCUMENTS CN 101090721 12/2007 ( 22 ) Filed : Jul. 16 , 17 KR 2007 0017136 2/2007 WO 2005/065308 7/2005 (65 ) Prior Publication Data WO 2005/079756 9/2005 WO 2011044089 4/2011 US 2017/0312275 A1 Nov. 2 , 2017 WO 2012/104852 8/2012 WO 2005/000216 9/2013 WO 2013138322 9/2013 Related U.S. Application Data (63 ) Continuation of application No.
    [Show full text]
  • New Use of Glutaminyl Cyclase Inhibitors
    (19) TZZ _Z T (11) EP 2 481 408 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 01.08.2012 Bulletin 2012/31 A61K 31/4164 (2006.01) A61K 31/4184 (2006.01) A61K 31/422 (2006.01) A61K 31/4178 (2006.01) (2006.01) (2006.01) (21) Application number: 11192085.6 A61K 31/433 A61K 31/5415 A61K 31/517 (2006.01) A61P 25/28 (2006.01) (2006.01) (2006.01) (22) Date of filing: 28.02.2008 A61P 29/00 A61P 3/08 A61K 45/06 (2006.01) (84) Designated Contracting States: • Hoffmann, Torsten AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 06114 Halle / Saale (DE) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • Cynis, Holger RO SE SI SK TR 06110 Halle / Saale (DE) • Demuth, Hans-Ulrich (30) Priority: 01.03.2007 US 892265 P 06120 Halle / Saale (DE) 14.03.2007 US 685881 (74) Representative: Hoffmann, Matthias et al (62) Document number(s) of the earlier application(s) in Maikowski & Ninnemann accordance with Art. 76 EPC: Patentanwälte 08717208.6 / 2 117 540 Kurfürstendamm 54-55 10707 Berlin (DE) (71) Applicant: Probiodrug AG 06120 Halle/Saale (DE) Remarks: This application was filed on 06-12-2011 as a (72) Inventors: divisional application to the application mentioned • Schilling, Stephan under INID code 62. 06130 Halle / Saale (DE) (54) New use of glutaminyl cyclase inhibitors (57) The present invention relates in general to an c. fibrosis, e.g. lung fibrosis, liver fibrosis, renal fibrosis, inhibitor of a glutaminyl peptide cyclotransferase, and d.
    [Show full text]
  • Pharmacology of a Novel Biased Allosteric Modulator for NMDA Receptors
    Pharmacology of a Novel Biased Allosteric Modulator for NMDA Receptors Lina Kwapisz Thesis submitted to the faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of Master of Science In Biomedical and Veterinary Sciences B. Costa, Co-Chair B. Klein M. Theus C. Reilly April 28th of 2021 Blacksburg, VA Keywords: NMDAR, allosteric modulation, CNS4, glutamate Pharmacology of a Novel Biased Allosteric Modulator for NMDA Receptors Lina Kwapisz ABSTRACT NMDA glutamate receptor is a ligand-gated ion channel that mediates a major component of excitatory neurotransmission in the central nervous system (CNS). NMDA receptors are activated by simultaneous binding of two different agonists, glutamate and glycine/ D- serine1. With aging, glutamate concentration gets altered, giving rise to glutamate toxicity that contributes to age-related pathologies like Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and dementia88,95. Some treatments for these conditions include NMDA receptor blockers like memantine130. However, when completely blocking the receptors, there is a restriction of the receptor’s normal physiological function59. A different approach to regulate NMDAR receptors is thorough allosteric modulators that could allow cell type or circuit-specific modulation, due to widely distributed GluN2 expression, without global NMDAR overactivation59,65,122. In one study, we hypothesized that the compound CNS4 selectively modulates NMDA diheteromeric receptors (GluN2A, GluN2B, GuN2C, and GluN2C) based on (three) different glutamate concentrations. Electrophysiological recordings carried out on recombinant NMDA receptors expressed in xenopus oocytes revealed that 30μM and 100μM of CNS4 potentiated ionic currents for the GluN2C and GluN2D subunits with 0.3μM Glu/100μM Gly.
    [Show full text]
  • WO 2011/089216 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date t 28 July 2011 (28.07.2011) WO 2011/089216 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/48 (2006.01) C07K 1/13 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 1/1 07 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/050821 HN, HR, HU, ID, J , IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 2 1 January 201 1 (21 .01 .201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1015 1465. 1 22 January 2010 (22.01 .2010) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): AS- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, CENDIS PHARMA AS [DK/DK]; Tuborg Boulevard TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 12, DK-2900 Hellerup (DK).
    [Show full text]